Key Highlights

  • Second-quarter total Revenue was $214 million, up 15% year over year, with surgical revenue up 17% to $196 million, driven by 20% case-volume growth.
  • The GAAP net loss narrowed to $25.8 million from $41.1 million, and on a non-GAAP basis the company reported Net Income of $11.4 million.
  • Adjusted EBITDA grew to $36 million, a 16.8% margin, expanding 420 basis points year over year, with $119 million in cash and positive free cash flow.
  • Alphatec reaffirmed roughly $882 million in full-year 2026 revenue and raised its adjusted EBITDA guidance to about $140 million.

Alphatec Holdings (NASDAQ:ATEC), a company focused on spine-surgery technology, has been growing on the strength of rapid revenue growth, narrowing losses and expanding profitability, along with a raised Earnings outlook. For investors, the combination of strong top-line momentum and improving margins raises the question of whether the company can sustain its trajectory as it scales its differentiated spine platform.

Alphatec develops innovative spine-surgery implants, instruments and data-analytics tools designed to improve surgical procedures and patient outcomes, and it has been rapidly gaining share by attracting new surgeon users and growing surgical case volumes. Its integrated approach, combining hardware with informatics and imaging including its EOS platform, differentiates it in the competitive spine market and has driven consistent double-digit growth.

Latest Developments

In its second-quarter 2026 results, Alphatec reported total revenue of $214 million, up 15% year over year, with surgical revenue up 17% to $196 million, driven by 20% case-volume growth and a 24% increase in net new surgeon users. The GAAP net loss narrowed to $25.8 million from $41.1 million, and on a non-GAAP basis the company reported net income of $11.4 million. Adjusted EBITDA grew to $36 million, a 16.8% margin, expanding 420 basis points year over year. The company ended the quarter with $119 million in cash and generated positive free cash flow. It reaffirmed roughly $882 million in full-year 2026 revenue and raised its adjusted EBITDA guidance to about $140 million, while targeting at least $20 million in free cash flow.

Financial and Business Position

Alphatec's results show a company executing well: strong revenue and case-volume growth, rapid surgeon adoption, narrowing losses and meaningful Margin expansion. The raised adjusted EBITDA guidance and the shift to positive free Cash Flow are important markers that its growth is becoming more profitable and self-funding. The company's differentiated, technology-enabled spine platform and its success in attracting new surgeons underpin its share gains, though it continues to report GAAP losses as it invests in growth.

Stock-Market Context

The company carries a strong-buy analyst rating, reflecting the strong growth and improving profitability. The case for continued strength rests on continued double-digit revenue and case-volume growth, sustained margin expansion toward and beyond the raised EBITDA guidance, and the shift to positive free cash flow; the cautionary case is that the company still posts GAAP losses, and that the spine market is competitive.

What Investors Should Watch

Investors may focus on surgical-revenue and case-volume growth, new surgeon-user additions, adjusted-EBITDA margin expansion against the raised guidance, free-cash-flow generation, and the contribution of its EOS imaging platform. Evidence that Alphatec can sustain its rapid growth while continuing to expand margins and generate cash would do the most to confirm the durability of its momentum.

Alphatec has emerged as one of the most compelling growth stories in the spine-surgery market, gaining share rapidly by attracting new surgeons and growing case volumes through a differentiated, technology-enabled platform that integrates implants, instruments, informatics and imaging. The raised adjusted EBITDA guidance is a particularly important signal, indicating that management sees the growth becoming more profitable and self-funding. For investors, the case rests on Alphatec sustaining its rapid growth while continuing to expand margins and generate cash, which would validate the transition from a growth-at-all-costs company to a profitably growing spine leader.